{
    "paper_id": "PMC7218667",
    "metadata": {
        "title": "Continue ACE inhibitors/ ARB\u2019S till further evidence in Coronavirus disease 2019 (COVID-19)",
        "authors": [
            {
                "first": "Sandeep",
                "middle": [],
                "last": "Bansal",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Sourabh",
                "middle": [],
                "last": "Agstam",
                "suffix": "",
                "email": "sourabhagstam@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Anunay",
                "middle": [],
                "last": "Gupta",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Preeti",
                "middle": [],
                "last": "Gupta",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "H.S.",
                "middle": [],
                "last": "Isser",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Angiotensin-converting enzyme inhibitors (ACEi) inhibits angiotensin-converting enzyme (ACE). ACE catalyzes Angiotensin I to angiotensin II. Few animal (rat) studies showed the beneficial effects of ACEi by upregulating ACE 2 mRNA level. A similar effect had been seen by ARB\u2019s by upregulating messenger RNA (mRNA) of ACE2 and increasing ACE 2 level.3, 4, 5\n",
            "cite_spans": [
                {
                    "start": 350,
                    "end": 351,
                    "mention": "3",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 353,
                    "end": 354,
                    "mention": "4",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 356,
                    "end": 357,
                    "mention": "5",
                    "ref_id": "BIBREF6"
                }
            ],
            "section": "Effects of ACEi/ARB\u2019s on ACE2 level",
            "ref_spans": []
        },
        {
            "text": "Contrary to previous studies, recent animal studies showed no effect of ACEi/ARBs on ACE2 gene expression.6 Likewise, human studies of ACEi/ARB\u2019s showed conflicting results.7, 8, 9\n",
            "cite_spans": [
                {
                    "start": 106,
                    "end": 107,
                    "mention": "6",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 173,
                    "end": 174,
                    "mention": "7",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 176,
                    "end": 177,
                    "mention": "8",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 179,
                    "end": 180,
                    "mention": "9",
                    "ref_id": "BIBREF10"
                }
            ],
            "section": "Effects of ACEi/ARB\u2019s on ACE2 level",
            "ref_spans": []
        },
        {
            "text": "In SARS-Cov-2, ACE2 acts as a receptor for the entry of viruses inside the cell. Theoretically, upregulation of ACE2 by ACE i/ARB\u2019s helps the entry of virus inside cell; however, no study showed the deleterious effect of ACEi/ARB\u2019s in Covid-19 patients or causal relationship among ACEi/ARB\u2019s with COVID-19.10\n",
            "cite_spans": [
                {
                    "start": 307,
                    "end": 309,
                    "mention": "10",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Effects of ACEi/ARB\u2019s on ACE2 level",
            "ref_spans": []
        },
        {
            "text": "There is robust evidence of the mortality-lowering effects of ACEi/ARB\u2019s in heart failure and postmyocardial infarction. Sudden discontinuation of heart failure therapy leads to precipitation of heart failure. Similarly, ACEi/ARB\u2019s, are part of the standard therapy in hypertension, and sudden withdrawal will cause rebound hypertension. Recent literature firmly emphasizes on the continuation of these drugs.2\n,\n11\n",
            "cite_spans": [
                {
                    "start": 409,
                    "end": 410,
                    "mention": "2",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 413,
                    "end": 415,
                    "mention": "11",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "Effects of ACEi/ARB\u2019s on ACE2 level",
            "ref_spans": []
        },
        {
            "text": "Current evidence doesn\u2019t support withdrawal of ACEi/ARB\u2019s in the population already on these drugs. We should continue using these drugs to prevent mortality due to heart failure and myocardial infarction, until further research on SARS-Cov-2 interaction with ACEi/ARB\u2019s shows a strong reason to stop these drugs.",
            "cite_spans": [],
            "section": "Effects of ACEi/ARB\u2019s on ACE2 level",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "FIGREF0": {
            "text": "Figure 1: SARS-Cov-2 virus enters into cell through angiotensin converting enzyme 2 (ACE 2) receptor on lung membrane, replicates and further downregulates ACE 2. The physiological function of ACE 2 is to degrade angiotensin II. Downregulation of ACE 2 by virus leads to increase in Angiotensin II, which causes systemic injury. Angiotensin converting enzyme inhibitors (ACEi) block ACE and aldosterone receptors blockers (ARB\u2019s) block angiotensin II blockers. Red arrow depicts negative regulation and blue arrow depicts positive regulation. SARS-Cov-2 (Severe acute respiratory syndrome- Coronavirus 2).",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Ramakrishnan",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Zachariah",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Gupta",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Indian Heart J",
            "volume": "71",
            "issn": "4",
            "pages": "309-313",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 [published online ahead of print, 2020 Mar 30]",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Vaduganathan",
                    "suffix": ""
                },
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Vardeny",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Michel",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMsr2005760"
                ]
            }
        },
        "BIBREF4": {
            "title": "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2",
            "authors": [
                {
                    "first": "C.M.",
                    "middle": [],
                    "last": "Ferrario",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Jessup",
                    "suffix": ""
                },
                {
                    "first": "M.C.",
                    "middle": [],
                    "last": "Chappell",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Circulation",
            "volume": "111",
            "issn": "20",
            "pages": "2605-2610",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 Mas receptor",
            "authors": [
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Sukumaran",
                    "suffix": ""
                },
                {
                    "first": "P.T.",
                    "middle": [],
                    "last": "Veeraveedu",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Gurusamy",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Mol Cell Endocrinol",
            "volume": "351",
            "issn": "",
            "pages": "208-219",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 Mas receptor",
            "authors": [
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Sukumaran",
                    "suffix": ""
                },
                {
                    "first": "P.T.",
                    "middle": [],
                    "last": "Veeraveedu",
                    "suffix": ""
                },
                {
                    "first": "A.P.",
                    "middle": [],
                    "last": "Lakshmanan",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Free Radic Res",
            "volume": "46",
            "issn": "",
            "pages": "850-860",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions",
            "authors": [
                {
                    "first": "L.J.",
                    "middle": [],
                    "last": "Burchill",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Velkoska",
                    "suffix": ""
                },
                {
                    "first": "R.G.",
                    "middle": [],
                    "last": "Dean",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Clin Sci (Lond)",
            "volume": "123",
            "issn": "",
            "pages": "649-658",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation",
            "authors": [
                {
                    "first": "D.J.",
                    "middle": [],
                    "last": "Campbell",
                    "suffix": ""
                },
                {
                    "first": "C.J.",
                    "middle": [],
                    "last": "Zeitz",
                    "suffix": ""
                },
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Esler",
                    "suffix": ""
                },
                {
                    "first": "J.D.",
                    "middle": [],
                    "last": "Horowitz",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Hypertens",
            "volume": "22",
            "issn": "",
            "pages": "1971-1976",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Furuhashi",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Moniwa",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Mita",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Am J Hypertens",
            "volume": "28",
            "issn": "",
            "pages": "15-21",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Epelman",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Shrestha",
                    "suffix": ""
                },
                {
                    "first": "R.W.",
                    "middle": [],
                    "last": "Troughton",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "J Card Fail",
            "volume": "15",
            "issn": "",
            "pages": "565-571",
            "other_ids": {
                "DOI": []
            }
        }
    }
}